Q2 2027 McKesson Corporation Earnings Conference Call - MCKESSON CORP

Financial Performance:

• Consolidated revenue increased 8% year-over-year to $111 billion, driven by growth across all four operating segments.
• Gross profit rose 10% to $3.9 billion, supported by higher prescription volumes and specialty product strength.
• Operating profit increased 13% to $1.9 billion, with operating expenses as a percentage of gross profit improving by 141 basis points.
• Adjusted earnings per diluted share (EPS) increased 18% to $11.68; excluding prior year one-time items, adjusted EPS grew 24%.
• North American pharmaceutical revenue grew 6% to $91.4 billion; GLP-1 distribution revenue reached $1.6 billion (up 26% YoY).
• Free cash flow for the quarter was $2.9 billion, with $990 million returned to shareholders via share repurchases ($3.4 billion YTD) and dividends.
• Cash and cash equivalents stood at $6.5 billion with total liquidity of $11.5 billion.
• Effective tax rate was 17.8%, including $105 million in net discrete tax benefits.

Guidance and Future Outlook:

• Fiscal 2027 adjusted EPS guidance raised to $45.60–$46.40 (previously $44.20–$45.00).
• Implies fiscal 2027 adjusted EPS growth of 17–19% (excluding prior year one-time items) and 19–21% including them, exceeding the long-term target of 13–16%.
• Full-year fiscal 2027 revenue growth expected between 6–10%; operating profit growth anticipated at 12–16%.
• Fiscal 2027 free cash flow projected at $4.5–$4.9 billion.
• Expected share repurchases for fiscal 2027 are approximately $5 billion (vs. $3.4 billion YTD).
• Segment outlooks: North American pharma (revenue +5–9%, op profit +14–18%); Oncology/Multispecialty (revenue +20–24%, op profit +18–22%); Prescription Technology (revenue +2.5–6.5%, op profit +11–15%); MedSurge (revenue +1–6%, op profit flat to -4%).

Business Segments and Product Lines:

• North American Pharmaceutical: Strong growth in specialty distribution, health systems, and strategic accounts; revenue supported by GLP-1 demand.
• Oncology and Multispecialty: Revenue up 24% driven by provider solutions (GPO services) and specialty distribution; expanded footprint with addition of Spectrum Vision Partners to PRISM Vision Group.
• Prescription Technology Solutions: Revenue up 10%; growth driven by access/affordability solutions, including the new CMS Medicare GLP-1 Bridge Program starting July 1.
• Medical-Surgical Solutions: Revenue up 5% driven by extended care channels; operating profit declined 10% due to ambulatory care mix shifts.
• Strategic Acquisitions: Completed acquisition of Precision Medicine Group (PMG) for ~$2.25 billion; reported within Oncology and Multispecialty segment, expected to be accretive to EPS by $1.60–$1.80 by end of year three.
• Strategic Investment: Signed agreement to invest $1.4 billion for a 49% minority stake in Option Care Health (expected to close H1 calendar year 27); reported via equity method, not affecting segment margins.

Market and Competitive Landscape:

• Strong market trends in oncology and specialty therapeutics, with stable utilization and innovation driving demand.
• Renewed 25-year pharmaceutical distribution agreement with CVS Health (term starting Oct 1, 2026).
• Payer network expanded to cover 96% of U.S. prescription volume.
• GLP-1 market continues to show robust demand, though utilization varies quarterly based on payer dynamics.
• Biosimilars and new drug launches present opportunities for access and affordability solutions.

Risks and Challenges:

• Policy and Regulatory: Impact of potential 340B rebate model implementation in January 2027 and changes to OPPS remain uncertain; management does not anticipate material financial impact but will monitor customer behavior closely.
• Pricing Pressures: Branded pharmaceutical pricing decreases (WAC declines) reduce revenue but have minimal impact on operating profit due to volume leverage.
• Supply Chain and Operational: Seasonal variability in illness seasons impacts Medical-Surgical solutions; quarterly variability in Prescription Technology due to program timing and payer requirements.
• Integration Risks: PMG integration involves adding CRO capabilities (new to McKesson), though synergies are expected to ramp up.

Management Commentary and Tone:

• Tone is highly confident and positive, citing "broad-based growth" and "disciplined execution."
• Management emphasizes the success of their strategic priorities in oncology, biopharma services, and community-based care.
• Brian Tyler (CEO) and Kenny Chung (CFO) expressed strong conviction in the business fundamentals and long-term value creation.
• Management highlighted the completion of the PMG acquisition and the strategic fit of the Option Care investment as key milestones.

Analyst Questions and Answers:

• Segment Reporting & Margins: Analyst asked about PMG/Option Care reporting; confirmed PMG reports in Oncology/Multispecialty (higher margin profile) and Option Care is equity method (no segment margin impact).
• GLP-1 & Biosimilars: Addressed GLP-1 volume variability and biosimilar launch impacts; noted pricing impacts are revenue-focused, not profit-focused.
• 340B Policy: Discussed potential 340B rebate model changes post-election; management remains engaged with customers and expects to navigate changes without material financial impact.
• Integration Complexity: Clarified that PMG integration is "complementary" with low overlap, while Option Care is a minority investment run by CD&R, reducing integration complexity for McKesson.
• Long-Term Growth: Confirmed that current Q2 outperformance (22% op profit growth) is supported by structural drivers and will continue, though long-term targets (13–16% EPS growth) remain the benchmark.

Other Key Points:

• Launched "Family Forward," an employee resource group for caregivers, alongside 11 other existing groups.
• The U.S. Oncology Network joint venture with Sarah Cannon Research Institute (SCRI) serves as a foundation for the PMG acquisition, expanding clinical trial capabilities.
• Management expects accelerated investments in technology and automation in the second half of fiscal 2027.
• Interest expense for fiscal 2027 is projected to be $380–$420 million due to higher borrowing rates.
• Diluted weighted average shares outstanding for fiscal 2027 expected to be 115.5–117.5 million.